Top institutional investors include Silverarc Capital Management LLC (0.30%), Barclays PLC (0.13%), Prudential Financial Inc. (0.11%), Strs Ohio (0.08%), Janney Montgomery Scott LLC (0.07%) and Los Angeles Capital Management LLC (0.07%). Investors and News | Seres Therapeutics Facebook Updated daily, it takes into P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Sie knnen Ihre Einstellungen jederzeit ndern. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. To see all exchange delays and terms of use please see Barchart's disclaimer. Seres Therapeutics to Present at World Anti-Microbial Resistance Congress, Why Seres Therapeutics Shares Are Popping Off Today, Seres Completes Rolling BLA Submission To FDA For SER-109 For Prevention Of RCDI, Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection, Calculating The Intrinsic Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB), Analysts Are Betting On Seres Therapeutics, Inc. (NASDAQ:MCRB) With A Big Upgrade This Week, Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher, Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference, Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates, Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates, Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022. Please log in to your account or sign up in order to add this asset to your watchlist. View our MCRB earnings forecast. Seres Therapeutics stock traded down $0.96 during midday trading on Friday, reaching $8.03. Oct 27, 2022. Whether youre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Copyright 2022 Surperformance. Seres Therapeutics, Inc. Forecasted to Post Q2 2023 Earnings of $0.49 Seres Therapeutics (MCRB) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45. Seres Therapeutics, Inc. (MCRB) Stock Price, News, Quote - Yahoo! Seres Therapeutics Inc. (MCRB) Sitting On The Launchpad, Waiting For Seres Therapeutics has a 12 month low of $2.50 and a 12 month high of $11.69. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics Stock: Here We Go Again (NASDAQ:MCRB) Get the latest Seres Therapeutics, Inc. (MCRB) stock news and headlines to help you in your trading and investing decisions. There are currently 3 buy ratings for the stock. This compares to earnings of $0.72 per share a year ago. Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. The Seres Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022. What is Seres Therapeutics' stock price today? Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. UNIT, ARCT and MCRB are among after hour movers. Earnings for Seres Therapeutics are expected to grow in the coming year, from ($2.22) to ($1.11) per share. Nestle paid $175 million (and more coming) for these rights. Why Seres Therapeutics Stock Skyrocketed 350% Today Seres Therapeutics Stock Soars on Positive Trial Results - Market Realist Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com Stock analysis for Seres Therapeutics Inc (MCRB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Jun-19-22 10:47AM. Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load? Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. 8,173 shares of the stock traded hands, compared to its average volume of 848,306. Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Invest.. Seres Therapeutics Gets FDA Acceptance of BLA for SER-109. Seres Therapeutics: The Good And The Challenging - SeekingAlpha The biotechnology company earns $-65,580,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. Investors and News. Will The Rally Continue In Seres Therapeutics (MCRB) Stock After A 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 Product overview. account day-to-day movements in market value compared to a companys liability structure. Durch Klicken auf Alle akzeptieren erklren Sie sich damit einverstanden, dass Yahoo und seine Partner Ihre personenbezogenen Daten verarbeiten und Technologien wie Cookies nutzen, um personalisierte Anzeigen und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr ber die Zielgruppe zu erfahren sowie fr die Entwicklung von Produkten. Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). One share of MCRB stock can currently be purchased for approximately $8.14. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. MCRB: Seres Therapeutics Inc - Stock Price, Quote and News - CNBC Seres Therapeutics stock opened at $8.14 on Friday. Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022. Seres Therapeutics Stock Performance. By creating a free account, you agree to our. The share price crashed when SER-287 failed in an Ulcerative Colitis trial; a new trial with SER-301 is planned. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. Seres Therapeutics stock opened at $8.14 on Friday. Shares of Seres Therapeutics ( MCRB 0.31%) soared on Monday after the biotech company announced promising results from a phase 3 study of its experimental therapy for colon infections. YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts. VP & Sec. SER-109 is a potential first-in-class investigational microbiome therapeutic administered orally following antibiotics designed to reduce recurrence of C. difficile infection (CDI) in patients with recurrent CDI. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Only 4.20% of the stock of Seres Therapeutics is held by insiders. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Journal of the American . Recent News. Le mdicament candidat de Seres Therapeutics contre les infections du clon obtient une.. Seres Therapeutics annonce l'acceptation par la FDA de la demande de licence de produit.. Seres Therapeutics, Inc. annonce la publication de donnes cliniques de phase 3 dans le.. Seres Therapeutics conclut la soumission la FDA d'une demande d'autorisation de mise .. Piper Sandler Adjusts Price Target on Seres Therapeutics to $9 From $7, Reiterates Over.. Chardan Capital Lowers Seres Therapeutics Price Target to $12 From $16, Maintains Buy R.. Oppenheimer Adjusts Seres Therapeutics' Price Target to $12 From $13, Maintains Outperf.. Virtus LifeSci Biotech Clinical Trials ETF - USD, ETFs S&P Biotech ETF - Distributing - AUD, BMO MSCI Genomic Innovation Index ETF - CAD, IShares Nasdaq US Biotechnology (D) - USD, President, Chief Executive Officer & Director, EVP, Chief Financial & Accounting Officer. Should I buy or sell Seres Therapeutics stock right now? 77% of retail CFD accounts lose money, Seres Therapeutics (MCRB) Gets a Buy from Chardan Capital, Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB), Seres Therapeutics (MCRB) and Personalis (PSNL), Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates, Seres Therapeutics GAAP EPS of -$0.49 misses by $0.02, revenue of $3.44M misses by $3.57M. The biotechnology company earned $3.44 million during the quarter, compared to analyst estimates of $12.29 million. Seres Therapeutics, Inc. Do the numbers hold clues to what lies ahead for the stock? Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Diseas Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infec Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates, Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Shares of Seres Therapeutics stock opened at $8.14 on Friday. With its current market valuation of $848.65 million, Seres Therapeutics Inc. is set to declare its quarterly results on Nov 02, 2022. Seres Therapeutics, Inc. is a microbiome therapeutics platform company. Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Is Seres Therapeutics Still A Buy After Disappointing SER-287 - Nasdaq Is Seres Therapeutics Stock A Buy? - Financhill As of 2022 October 17, Monday current price of MCRB stock is 6.880$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Seres Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 12% this week, taking one-year losses to 87%. Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American Colleg.. Seres therapeutics ecospor iii study data on ser-109 published in journal of the americ.. Seres Therapeutics, Inc. annonce ses rsultats pour le troisime trimestre et les neuf .. As of 3:35 . Daten ber Ihr Gert und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von Yahoo Websites und -Apps. Financial Juice The official website for the company is www.serestherapeutics.com. * Average Estimates in Million (e.g. Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates. Seres Therapeutics has a 12 month low of $2.50 and a 12 month high of $11.69. A high-level overview of Seres Therapeutics, Inc. (MCRB) stock. See what's happening in the market right now with MarketBeat's real-time news feed. MCRB Seres Therapeutics Inc Stock Price and Discussion - Stocktwits What is Seres Therapeutics' stock price forecast for 2023? Why Seres Therapeutics Stock Is Crashing Today - The Motley Fool View institutional ownership trends. Seres Therapeutics, Inc. (MCRB) Latest Stock News & Headlines - Yahoo! News | SERES THERAPEUTICS Stock Price Today - Insider Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds. Institutional investors are Seres Therapeutics, Inc.'s (NASDAQ:MCRB Open Positions. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA. Dies geschieht in Ihren Datenschutzeinstellungen. Seres Therapeutics, Inc. (NASDAQ:MCRB) released its quarterly earnings data on Wednesday, November, 2nd. View MCRB analyst ratings or view top-rated stocks. Seres Therapeutics, Inc. announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing recurrent C. difficile infection (rCDI . Seres Therapeutics, Inc. (MCRB) Stock Price Today, Quote & News Want to see which stocks are moving? Seres has had two share price crashes and one share price spike since listing. Get Seres Therapeutics Inc (MCRB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. ProShare Advisors LLC Sells 7,459 Shares of Seres Therapeutics, Inc 3 analysts have issued 12 month price objectives for Seres Therapeutics' shares. We are an exceptional team of drug . View the best growth stocks for 2022 here. If you had invested in Seres Therapeutics stock at $51.40, your return over the last 7 years would have been -82.39%, for an annualized return of -21.97% (not including any dividends or dividend reinvestments). Shares of MCRB stock can be purchased through any online brokerage account. MCRB Seres Therapeutics, Inc. Stock Quote - FINVIZ.com The P/E ratio of Seres Therapeutics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. How many employees does Seres Therapeutics have? What is Seres Therapeutics' stock symbol? Real-time trade and investing ideas on Seres Therapeutics Inc MCRB from the largest community of traders and investors. Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic S Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference, Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates, Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates. About Us. Every investor in Seres Therapeutics, Inc. (NASDAQ:MCRB) should be aware of the most powerful shareholder groups.We can see that institutions own the lion's share in the company with 61% ownership. Seres Therapeutics is a late-clinical-stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. Seres has a big (and . About Us - Seres Therapeutics The steep decline came after the company announced top-line results from a phase 2b clinical . Seres Therapeutics' stock is owned by many different institutional and retail investors. The firm has a market capitalization of $1.01 billion, a P/E ratio of -3.46 and a beta of 2.81. Dividend). 10/14 17:22. In 2021, MCRB's revenue was $144.93 million, an increase of 336.33% compared to the previous year's $33.22 million. Who are Seres Therapeutics' major shareholders? What other stocks do shareholders of Seres Therapeutics own? Klicken Sie auf Einstellungen verwalten, um weitere Informationen zu erhalten und Ihre Einstellungen zu verwalten. Realizing the possibilities within. MCRB - Seres Therapeutics Inc Stock quote - CNNMoney.com Compare Top Brokerages Here. 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 Europe Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference. These three events have resulted from bad (twice) and good (once) news from clinical trials. of Operations. Limit lab construction in the world's biotech capital? How do I buy shares of Seres Therapeutics? Learn about financial terms, types of investments, trading strategies, and more. Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022.